Single-source drug submissions under review (English, CSV)

Single-source drug submissions under review: English CSV file you can open as a table, filter, chart and export up to 10,000 rows. From Government of Ontario, updated Apr 2026.

Format
CSV
Access
Table on demand (prepared when opened)
Publisher-reported update
2026-04-17

Information on the status of manufacturers' drug submissions that allows industry stakeholders and the public to track the status of drug submissions through the various stages of the review cycle.

Access original file

Data overview

Formats
CSV
File languages
English
Available actions
Explore table (prepared automatically) · Access original file

Sample rows

The first 10 rows, as CanQuery read them from the start of the publisher's file on 2026-11-14.

Brand NameGeneric NameStrength and FormatManufacturerIndicationDate submission was deemed completeReview Status
Vyloyzolbetuximab100 mg vialAstellas Pharma Canada Inc.In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal grow…2025-06-19Negotiation
Enhertutrastuzumab deruxtecan100 mg/vialAstraZeneca Canada Inc.Monotherapy for the treatment of HER2-positive advanced gastric or gastroesophageal junction adenocarcinomas who have received a prior trastuzumab-based regimen2025-04-28Negotiation concluded
Weliregbelzutifan40 mg tabletMerck CanadaFor the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial g…2025-04-08Under review (CDA-AMC)
Weliregbelzutifan40 mg tabletMerck CanadaFor the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial g…2025-04-08Under review (CDA-AMC)
Winrevairsotatercept1x 45 mg kit, 1 x 60 mg kit, 2 x 45 mg kit, 2 x 60 mg kit, 45 mg vial, 60 mg vialMerck CanadaTreatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1)2025-03-10Negotiation
Darzalex SCdaratumumab120 mg/mL solutionJohnson & JohnsonIndicated in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed…2025-02-27Under review (CDA-AMC)
Luxa Dcholecalciferol2,000 IU, soft-gel capsuleOrimed Pharma Inc.For the treatment and prevention of vitamin D deficiency2025-02-18Review completed (CED)
Imdelltratarlatamab1 mg/vial, 10 mg/vialAmgen Canada Inc.For the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy2025-02-04Review completed (CDA-AMC)
Bimzelxbimekizumab320 mg/2 mL pre-filled syringe and autoinjectorUCB Canada Inc.For the treatment of moderate to severe plaque psoriasis (PsO) in adult patients who are candidates for systemic therapy or phototherapy2025-02-04Review completed CED)
Trecondyvtreosulfan5 g/vialMedexus Inc.In combination with fludarabine as part of conditioning treatment prior to alloHSCT in adult patients with AML or MDS at increased risk for standard conditioning therapies2025-01-22Negotiation concluded

Official sources and licences

Related open data